Patents Assigned to Bristol-Myers Squibb
  • Spirocyclic compounds useful as modulators of nuclear hormone receptor function
    Patent number: 7235563
    Abstract: Spirocyclic compounds, methods of using such spirocyclic compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds are disclosed.
    Type: Grant
    Filed: June 20, 2005
    Date of Patent: June 26, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventor: James Aaron Balog
  • Guanidine mimics as factor Xa inhibitors
    Patent number: 7235575
    Abstract: The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula I: or pharmaceutically acceptable salt forms thereof, wherein rings D-E represent guanidine mimics, which are useful as inhibitors of factor Xa.
    Type: Grant
    Filed: August 5, 2005
    Date of Patent: June 26, 2007
    Assignee: Bristol Myers Squibb Company
    Inventors: Patrick Y. Lam, Charles G. Clark, Celia Dominguez, John M. Fevig, Qi Han, Renhua Li, Donald J P Pinto, James R. Pruitt, Mimi L. Quan
  • Tyrosine kinase inhibitors
    Patent number: 7232826
    Abstract: The present invention provides compounds of Formula I or II that are useful as anti-cancer agents and other diseases that can be treated by inhibiting tyrosine kinase enzymes
    Type: Grant
    Filed: September 29, 2003
    Date of Patent: June 19, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Upender Velaparthi, Mark D. Wittman
  • Intermediates useful in preparing certain pyrrolotriazine compounds and process for making such intermediates
    Patent number: 7232901
    Abstract: Described herein is at least one pyrrolo[1,2-f][1,2,4]triazine-2,4(1H,3H)-dione, which is an intermediates useful in preparing 2,4-disubstituted pyrrolotriazine compounds, and at least one method for making such intermediate.
    Type: Grant
    Filed: June 27, 2006
    Date of Patent: June 19, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Harold Mastalerz, Guifen Zhang
  • Malonamides and malonamide derivatives as modulators of chemokine receptor activity
    Patent number: 7230133
    Abstract: The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.
    Type: Grant
    Filed: April 29, 2004
    Date of Patent: June 12, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventor: Percy Carter
  • Substituted fused bicyclic amines as modulators of chemokine receptor activity
    Patent number: 7230022
    Abstract: The present application describes modulators of CCR3 of formula (Ia) and (Ib): or pharmaceutically acceptable salt forms thereof, wherein Z, R1, R2, R3, R4, R5, R5?, R6, a, b, c, d, and u are as defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using said modulators are disclosed.
    Type: Grant
    Filed: February 17, 2005
    Date of Patent: June 12, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Douglas G. Batt, Percy H. Carter, Dean A. Wacker
  • Polynucleotides encoding novel guanylate binding proteins (GBP's)
    Patent number: 7226791
    Abstract: The present invention provides polynucleotides encoding human and murine guanylate binding protein polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The present invention further relates to diagnostic and therapeutic methods for applying the guanylate binding protein polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides, such as rheumatoid arthritis and/or conditions related to aberrant NF-?B activity, guanylate binding activity and GTPase activity. The present invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: June 1, 2004
    Date of Patent: June 5, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Julie Carman, Stephen J. Warner, Rolf-Peter Ryseck
  • 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
    Patent number: 7226942
    Abstract: Novel compounds are provided which are glycogen phosphorylase inhibitors which are useful in treating, preventing or slowing the progression of diseases requiring glycogen phosphorylase inhibitor therapy such as diabetes and related conditions (such as hyperglycemia, impaired glucose tolerance, insulin resistance and hyperinsulinemia), the microvascular complications associated with diabetes (such as retinopathy, neuropathy, nephropathy and delayed wound healing), the macrovascular complications associated with diabetes (cardiovascular diseases such as atherosclerosis, abnormal heart function, myocardial ischemia and stroke), as well as Metabolic Syndrome and its component conditions including hypertension, obesity and dislipidemia (including hypertriglyceridemia, hypercholesterolemia and low HDL), and other maladies such as non-cardiac ischemia, infection and cancer.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: June 5, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Philip M. Sher, Alexandra A. Nirschl, Wei Meng, Wllliam N. Washburn
  • Process for the preparation of rebeccamycin and analogs thereof
    Patent number: 7227019
    Abstract: The present invention relates to a method for making an indolopyrrolocarbazole of the general formula [I], where the method includes the step of reacting a bisindolylmaleimide compound with an oxidizing agent in the presence of an oxygen containing gas at a temperature and for a time sufficient to yield the indolopyrrolocarbazole compound of the general formula [I].
    Type: Grant
    Filed: September 13, 2002
    Date of Patent: June 5, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventor: Jianji Wang
  • Assays and peptide substrate for determining aggrecan degrading metallo protease activity
    Patent number: 7223834
    Abstract: This invention is directed to assays to determine the presence or absence of proteins that exhibit aggrecanase or ADMP activity. This invention also relates to peptides that acts as a substrates for ADMPs, their use in various assays to determine the presence or absence of ADMP activity, and their use as inhibitors of ADMP activity.
    Type: Grant
    Filed: October 12, 2001
    Date of Patent: May 29, 2007
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Jeffrey A. Miller, Elizabeth C. Arner, Robert A. Copeland, Gary L. Davis, Ruiqin Liu, Michael A. Pratta, Micky D. Tortorella
  • 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
    Patent number: 7223786
    Abstract: Novel compounds are provided which are glycogen phosphorylase inhibitors which are useful in treating, preventing or slowing the progression of diseases requiring glycogen phosphorylase inhibitor therapy such as diabetes and related conditions (such as hyperglycemia, impaired glucose tolerance, insulin resistance and hyperinsulinemia), the microvascular complications associated with diabetes (such as retinopathy, neuropathy, nephropathy and delayed wound healing), the macrovascular complications associated with diabetes (cardiovascular diseases such as atherosclerosis, abnormal heart function, myocardial ischemia and stroke), as well as Metabolic Syndrome and its component conditions including hypertension, obesity and dislipidemia (including hypertriglyceridemia, hypercholesterolemia and low HDL), and other maladies such as non-cardiac ischemia, infection and cancer.
    Type: Grant
    Filed: November 14, 2005
    Date of Patent: May 29, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Wei Meng, Philip M. Sher, Bruce A. Ellsworth, William N. Washburn
  • Polynucleotides encoding three novel human cell surface proteins with leucine rich repeats and immunologobulin folds, BGS2, 3, and 4 and variants thereof
    Patent number: 7223558
    Abstract: The present invention provides novel polynucleotides encoding BGS-2, 3, and 4 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-2, 3, and 4 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: July 11, 2002
    Date of Patent: May 29, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Shujian Wu, Stanley R. Krystek, Liana Lee, John N. Feder, Janet D. Cheng
  • Crystallographic structure of the androgen receptor ligand binding domain
    Patent number: 7225083
    Abstract: The first crystal structure of the androgen receptor ligand binding domain has been determined to 2.0 angstrom resolution. Disclosed are the coordinates for the crystal structure, and methods for determining agonists, partial agonists, antagonists, partial antagonists and selective androgen receptors modulators (SARMs) of the androgen receptor.
    Type: Grant
    Filed: June 28, 2004
    Date of Patent: May 29, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Roberto Weinmann, Howard M. Einspahr, Stanley R. Krystek, John S. Sack, Mark E. Salvati, John S. Tokarski, Ricardo M. Attar, Chihuei Wang
  • Tyrosine kinase inhibitors
    Patent number: 7223757
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.
    Type: Grant
    Filed: November 30, 2005
    Date of Patent: May 29, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark D. Wittman, Neelakantan Balasubramanian, Upender Velaparthi, Kurt Zimmermann, Mark G. Saulnier, Peiying Liu, Xiaopeng Sang, David B. Frennesson, Karen M. Stoffan, James G. Tarrant, Anne Marinier, Stephan Roy
  • Enzymatic ammonolysis process for the preparation of intermediates for DPP IV inhibitors
    Patent number: 7223573
    Abstract: An enzymatic ammonolysis process is provided for the preparation of intermediates used in preparing dipeptidyl peptidase IV inhibitors wherein the enzyme Candida antarctica lipase-B is used to catalyze the ammonolysis process.
    Type: Grant
    Filed: May 2, 2005
    Date of Patent: May 29, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ramesh N. Patel, Ronald L. Hanson, Iqbal Gill, David B. Brzozowski, Paul M. Skonezny, Michael M. Politino, Jason G. Chen, Francisco Moris-Varas, Brenda J. White
  • Polynucleotide encoding a TRP channel family member, TRP-PLIK2
    Patent number: 7223557
    Abstract: The present invention provides novel polynucleotides encoding TRP-PLIK2 polypeptides, fragments and homologues thereof. The present invention also provides polynucleotides encoding variants and splice variants of TRP-PLIK2 polypeptides, TRP-PLIK2b, TRP-PLIK2c, and TRP-PLIK2d, respectively. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing said polypeptides. The invention further relates to diagnostic and therapeutic methods for applying these novel TRP-PLIK2, TRP-PLIK2b, TRP-PLIK2c, and TRP-PLIK2d polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: May 22, 2002
    Date of Patent: May 29, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ning Lee, Jian Chen, John N. Feder, Shujian Wu, Han Chang, Liana M. Le, Michael A. Blanar, David Bol
  • Bicyclic heterocycles as cannabinoid receptor modulators
    Patent number: 7220859
    Abstract: The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R3a, R4, A, B, and n are described herein.
    Type: Grant
    Filed: January 12, 2006
    Date of Patent: May 22, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Richard B. Sulsky, William R. Ewing
  • Calcitonin gene related peptide receptor antagonists
    Patent number: 7220862
    Abstract: The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
    Type: Grant
    Filed: December 5, 2003
    Date of Patent: May 22, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Prasad V. Chaturvedula, Ling Chen, Rita Civiello, Andrew P. Degnan, Gene M. Dubowchik, Xiaojun Han, Xiang Jun J. Jiang, George N. Karageorge, Guanglin Luo, John E. Macor, Graham Poindexter, George Tora
  • Substituted heterocycle fused gamma-carbolines
    Patent number: RE39679
    Abstract: The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
    Type: Grant
    Filed: February 16, 2006
    Date of Patent: June 5, 2007
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Albert J. Robichaud, Taekyu Lee, Wei Deng, Ian S. Mitchell, Michael Guang Yang, Simon Haydar, Wenting Chen, Christopher D. McClung, Emile J. B. Calvello, David M. Zawrotny, Parthasarathl Rajagopalan
  • Substituted heterocycle fused gamma-carbolines
    Patent number: RE39680
    Abstract: The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein R1, R5, R6a, R6b, R7, R8, R9, X, b, k, m, and n, and the dashed lines are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
    Type: Grant
    Filed: February 16, 2006
    Date of Patent: June 5, 2007
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Albert J. Robichaud, Taekyu Lee, Wei Deng, Ian S. Mitchell, Michael Guang Yang, Simon Haydar, Wenting Chen, Christopher D. McClung, Emile J. B. Calvello, David M. Zawrotny, Parthasarathl Rajagopalan